Research Article

Oral and Topical Centella asiatica in Type 2 Diabetes Mellitus Patients with Dry Skin: A Three-Arm Prospective Randomized Double-Blind Controlled Trial

Table 2

SRRC, SCap, CML, IL-1α, and SOD activity based on the intervention group (N = 159).

VariableCAo + CAt (n = 53)Plo + CAt (n = 53)Plo + Plt (n = 53) value

SRRC
 D 10.07
  Median (min–max)4 (3–10)4 (3–8)5 (3–8)
 D 150.48
  Median (min–max)2 (0–6)3 (0–7)3 (0–7)
 D 290.71
  Median (min–max)2 (0–6)2 (0–7)2 (0–6)
SCap (AU)
 D 10.34
  Median (min–max)27.7 (10.4–36.4)25.4 (10.7–37.8)26.2 (12.1–46)
 D 150.38
  Median (min–max)37.6 (14.5–61.6)35.9 (12.5–61)35 (16.1–59.9)
 D 290.39
  Median (min–max)43.5 (14.5–65.9)44.6 (13.1–64)38.5 (16.9–63.7)
CML (pg/mg protein)
 D 10.79
  Median (min–max)87.2 (20.12–14559.42)77.2 (4.1–385.7)93.9 (14–407.8)
 D 290.41
  Median (min–max)119.8 (24.2–615.9)119.4 (25.2–1731.4)104.8 (22–748.1)
IL-1α (pg/mg protein)
 D 10.60
  Median (min–max)16.5 (2.9–167.3)16 (2.1–110.5)17.6 (4.4–114.6)
 D 290.68
  Median (min–max)19.7 (3.2–167.3)18.2 (4.9–69.6)17.6 (4.9–114.5)
SOD (U/mg protein)
 D 10.31
  Median (min–max)4.6 (0.3–59.4)3.4 (0.3–41.5)3.9 (0.2–35)
 D 290.07
  Median (min–max)5.9 (1–59.4)4.3 (0.2–18.7)4.9 (0.1–23.6)

Kruskal–Wallis test was performed to assess the difference.